Protagonist Therapeutics, INC 10-Q quarterly reports

Protagonist Therapeutics, Inc. announced substantial revenue growth and a strong cash position in its Q2 2026 10-Q filing, driven by key collaboration milestones.

Protagonist Therapeutics announced strong Q1 2026 results driven by the FDA approval of ICOTYDE, with significant revenue growth and a positive net income.

Protagonist Therapeutics reported a net loss of $39.3 million for Q3 2025, driven by increased R&D spending on new drug candidates, while advancing its Phase 3 programs for icotrokinra and rusfertide.

Protagonist Therapeutics submitted an NDA for icotrokinra and reported positive Phase 3 results for rusfertide, despite a net loss for the quarter due to lower collaboration revenue.

Protagonist Therapeutics' Q1 2025 results show a net loss of $11.655 million, but are highlighted by $28.321 million in license and collaboration revenue, primarily from the Takeda agreement.

Protagonist Therapeutics reports a robust cash position of $583.3 million, driven by a $300 million upfront payment from Takeda, while advancing its clinical programs for rusfertide and JNJ-2113.

Protagonist Therapeutics reports a significant increase in cash and marketable securities, driven by a $300 million upfront payment from Takeda, while also detailing ongoing clinical trials and financial results for the quarter ended June 30, 2024.

Protagonist Therapeutics reports a significant increase in revenue and a shift to profitability in Q1 2024, primarily due to a major collaboration agreement with Takeda Pharmaceuticals.